Introduction

Fibromyalgia syndrome (FMS) is a chronic syndrome characterized by widespread pain with specific tender areas (1). Although the etiology of FMS is unknown, this syndrome is occasionally accompanied by rheumatoid arthritis and other autoimmune diseases (1). Several effective methods have been reported for the treatment of pain in patients with FMS. In addition to the use of anti-depressants and a new anti-convalsant (2), exercise and spa therapy have been suggested to improve the symptoms in FMS patients
. However, the severity of symptoms in FMS patients varies widely, and exercise and spa therapy cannot be applied in many patients with disabilities in daily life due to their compromised physical condition. Therefore, improved methods for the treatment of such patients are necessary. A far infrared-ray dry sauna maintained at a constant temperature of 60 has been shown to be a safe form of therapy in patients with a compromised physical condition, such as those with heart failure (4) (5) (6) as well as peripheral artery disease (7) . Thermal therapy has been shown to improve hemodynamics in congestive heart failure by thermal vasodilation, as well as to relieve pain, improve walking ability and blood flow in patients with peripheral artery disease. Further, there was a decrease in subjective complaints among mildly depressed patients after thermal therapy (8 
T a b l e 1 . P a t i e n t s ' Ch a r a c t e r i s t i c s
we have been improving and refining over the past 18 years. The temperature of 60 is lower than conventional saunas and obviating the discomfort from heat stimulation of sympathetic nerve systems (4) . Additionally, our previous reports showed the efficacy of Waon therapy in reducing various subjective symptoms of patients with depression or chronic fatigue syndrome, alongside benefits observed for heart failure and peripheral artery disease patients (8, 9) . Recently, our paper entitled "Waon therapy" was published (11) and subsequently, the new terminology has become widely known and used worldwide. (4) .
Patients and Methods
Patients
Estimation of therapeutic effect
All patients rated their severity of pain using the visual F i g u r e 1 . T h e b a r g r a p h s h o ws t h e me a n ± S D s c o r e s o f p a i n o n t h e v i s u a l a n a l o g s c a l e ( VAS ) b e f o r e a n d a f t e r t h e 1 s t a n d D o f f i b r o my a lg i a i mp a c t q u e s t i o n n a i r e ( F I Q) s c o r e s b e f o r e a n d a f t (12) (9) . Although the precise mechanism of pain reduction by Waon therapy is unclear, mild warming of the whole body has been shown to exhibit sedative effects via the sensory nerve endings (14) . Waon therapy also promotes capillary dilatation and relieves muscular spasms related to tonic muscle contraction and pain (15) . A recent study indicated the involvement of oxidative stress in the pathogenesis of FMS (16) . In addition, Waon therapy has also been reported to reduce the levels of oxidative stress (17) . Although the present study included only 13 patients, the effects observed here were dramatic. Further clinical studies in larger FMS patient populations are required to confirm the effects of this method of treatment.
0 t h s e s s i o n s o f Wa o n t h e r a p y , a n d a t t h e f o l l o w-u p o b s e r v a t i o n . T h e VAS s c o r e s we r e i mp r o v e d a f t e r t h e s t s e ss i o n o f Wa o n t h e r a p y a n d t h e e f f e c t s we r e ma i n t a i n e d t h r o u g h o u t t h e o b s e r v a t i o n p e r i o d .
F i g u r e 2 . T h e b a r g r a p h s h o ws t h e me a n ± S
e r t h e 1 0 t h s e s s i o n o f Wa o n t h e r a p y a n d t h e f o l l o w-u p o b s e r v a t i o n . T h e F I Q s c o r e s we r e i mp r o v e d a f t e r Wa o n t h e r a p y a n d t h e e f f e c t s we r e ma i n t a i n e d t h r o u g h o u t t h e o b s e r v a t i o n p e r i o d . analog scale (VAS) before and after the first and 10th sessions of Waon therapy. Two patients (Nos. 1 and 2) were no longer under observation after the 10th therapy session, while the remaining eleven patients received follow-up and rated their pain symptoms using the VAS. The median follow-up period was 14 months (range: 6-30 months). Ten patients (Nos. 4-13) completed the Fibromyalgia Impact Questionnaire (FIQ)
